AGM Statement

Alliance Pharma PLC
21 June 2005

For Immediate Release                                          21 June 2005





                              ALLIANCE PHARMA PLC


                        Annual General Meeting Statement


Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
held its Annual General Meeting in London today, at which all resolutions were
duly passed.


At the meeting, Michael Gatenby, Alliance Pharma's Chairman, said:


'The first quarter has seen a continuation of the progress reported at our full
year results.  Sales have continued to grow, and are on target to meet
expectations.  At the full year we highlighted our improving gross margin, and I
am pleased to report that first quarter trading has continued to reflect this
trend.


'Good progress continues to be made with our development projects: Posidorm
(melatonin) for sleep disorders and Isprelor (misoprostol) for induction of
labour.


'In addition, and in line with our strategy, we will continue to seek high
quality, cash generative acquisitions of established prescription brands.'


At the Extraordinary General Meeting later the same day the Company Share Option
Scheme was approved.


                                       ENDS


For further information:

Alliance Pharma plc                                     + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk


Buchanan Communications                                 + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich



                      This information is provided by RNS
            The company news service from the London Stock Exchange